Compare Amgen, Inc. (AMGN) vs Bumble Inc (BMBL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Bumble Inc — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Bumble Inc trades at $3.01 (market cap $396.51M). The key difference: Amgen, Inc. is far larger — about 494.6× Bumble Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Bumble Inc pays none. Which is the better fit depends on your goals.
| AMGN | BMBL | |
|---|---|---|
Market Cap | $196.12B | $396.51M |
Sector | Health | Technology |
52-Week High | $388.16 | $8.57 |
52-Week Low | $271.18 | $2.70 |
Enterprise Value | $241.41B | $748.19M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Bumble Inc. (BMBL) trades at $3.03, down 1.3% on the day, reflecting ongoing investor concerns despite beating Q1 2026 EPS estimates. The stock shows bearish technical signals with neutral oscillators, while fundamentals reveal severe profitability challenges with a -71.04% net income margin and declining revenue. Recent news highlights strategic shifts including AI integration and exploration of a potential sale amid paid user declines.
The outlook remains highly speculative with significant execution risk. While valuation multiples appear distressed (P/S 0.38, P/B 0.64) suggesting potential upside, persistent losses and competitive pressures pose substantial downside risk. Analyst consensus leans Hold (73.91%) with a $4.37 price target, indicating cautious optimism contingent on successful product overhaul.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Bumble Inc
Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.
Read more on BMBL →
